{"id":580353,"date":"2021-12-27T18:24:02","date_gmt":"2021-12-27T18:24:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=580353"},"modified":"2021-12-27T18:24:02","modified_gmt":"2021-12-27T18:24:02","slug":"hereditary-angioedema-pipeline-therapeutic-assessment-emerging-drugs-clinical-trials-and-growth-prospects-key-players-csl-behring-takeda-shire-biocryst-ionis-pharma-kalvista-and-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/hereditary-angioedema-pipeline-therapeutic-assessment-emerging-drugs-clinical-trials-and-growth-prospects-key-players-csl-behring-takeda-shire-biocryst-ionis-pharma-kalvista-and-others_580353.html","title":{"rendered":"Hereditary Angioedema Pipeline: Therapeutic Assessment, Emerging Drugs, Clinical Trials, and Growth Prospects | Key Players- CSL Behring, Takeda, Shire, BioCryst, Ionis Pharma, KalVista, and Others"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Hereditary Angioedema Pipeline: Therapeutic Assessment, Emerging Drugs, Clinical Trials, and Growth Prospects | Key Players- CSL Behring, Takeda, Shire, BioCryst, Ionis Pharma, KalVista, and Others\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Hereditary Angioedema Pipeline: Therapeutic Assessment, Emerging Drugs, Clinical Trials, and Growth Prospects | Key Players- CSL Behring, Takeda, Shire, BioCryst, Ionis Pharma, KalVista, and Others\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">\u201cHereditary Angioedema Pipeline Insight, 2021&#8243; report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Hereditary Angioedema Market.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">The <strong>Hereditary Angioedema Pipeline report<\/strong> embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report also covers a detailed description of the drug including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" title=\"Hereditary Angioedema Pipeline Analysis\" src=\"https:\/\/www.abnewswire.com\/uploads\/c4d5188587672bf68a6bea9052bc476c.jpg\" alt=\"Hereditary Angioedema Pipeline Analysis\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/hereditary-angioedema-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Hereditary Angioedema Pipeline Analysis<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The report provides insights into:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report provides detailed insights about companies that are developing therapies for the treatment of <strong>Hereditary Angioedema<\/strong> with aggregate therapies developed by each company for the same.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the Hereditary Angioedema Treatment.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Hereditary Angioedema key companies<\/strong> involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Hereditary Angioedema Drugs<\/strong> under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Hereditary Angioedema market.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report is built using data and information traced from the researcher&#8217;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Request for Sample Pages @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hereditary-angioedema-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/hereditary-angioedema-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/hereditary-angioedema-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Hereditary Angioedema Therapeutics Landscape<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>Companies are focusing on executing a successful launch that meets the urgent demand for a once-daily oral therapy that will allow Hereditary Angioedema patients to live a more normal life. An orally delivered, small molecule offers the opportunity to improve treatment for the disease by making it more convenient for patients to take therapies.&nbsp;<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Some of the key companies in the Hereditary Angioedema Market include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">CSL Behring<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Takeda<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Shire<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Pharming Group<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">BioCryst Pharmaceuticals<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Ionis Pharmaceuticals<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">KalVista Pharmaceuticals<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Hereditary Angioedema Therapies covered in the report includes:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">KVD900&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">CSL312&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Takhzyro<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Firazyr<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Ruconest<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">BCX7353<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Berinert<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Haegarda<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Kalbitor<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Cinryze<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">IONIS-PKK-LRx&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many more<\/p>\n<p style=\"text-align: justify;\">&nbsp;<strong>Download Sample Pages @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hereditary-angioedema-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/hereditary-angioedema-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Content<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Hereditary Angioedema&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Hereditary Angioedema Current Treatment Patterns<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Hereditary Angioedema &#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Hereditary Angioedema Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Hereditary Angioedema Mid Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Hereditary Angioedema Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Hereditary Angioedema Product Profiles<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Hereditary Angioedema Key Companies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Hereditary Angioedema Key Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. Hereditary Angioedema Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Hereditary Angioedema Future Perspectives<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. Hereditary Angioedema Analyst Review&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>*The table of contents is not exhaustive; the final content may vary.&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Visit to get the sample report:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hereditary-angioedema-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/hereditary-angioedema-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_75707.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=hereditary-angioedema-pipeline-therapeutic-assessment-emerging-drugs-clinical-trials-and-growth-prospects-key-players-csl-behring-takeda-shire-biocryst-ionis-pharma-kalvista-and-others\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=hereditary-angioedema-pipeline-therapeutic-assessment-emerging-drugs-clinical-trials-and-growth-prospects-key-players-csl-behring-takeda-shire-biocryst-ionis-pharma-kalvista-and-others\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP \u201cHereditary Angioedema Pipeline Insight, 2021&#8243; report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Hereditary Angioedema Market. The Hereditary Angioedema Pipeline report embraces in-depth commercial and clinical assessment of &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/hereditary-angioedema-pipeline-therapeutic-assessment-emerging-drugs-clinical-trials-and-growth-prospects-key-players-csl-behring-takeda-shire-biocryst-ionis-pharma-kalvista-and-others_580353.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[435,405,406,403,404],"tags":[],"class_list":["post-580353","post","type-post","status-publish","format-standard","hentry","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/580353","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=580353"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/580353\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=580353"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=580353"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=580353"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}